LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will host a conference call to provide an update on the company’s discussions with the U.S. Food and Drug Administration regarding an update to the product label for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.
